Research
Hormonal
Genetic variants in GLP1R (rs6923761) and TCF7L2 (rs7903146) influence the response to liraglutide, with specific genotypes associated with greater reductions in body fat and weight.
If you are taking liraglutide, your genetic makeup might influence how much fat or weight you lose. Some genetic variants are linked to better outcomes with this drug. This is not a reason to start or stop treatment, but may help explain individual differences in response.
GoodQualifiesMEDIUM confidence
After 16 weeks of liraglutide, GLP1R rs6923761 (AG/AA vs. GG) was associated with reduced percent body fat (p = 0.062), and TCF7L2 rs7903146 (CC vs. CT/TT) was associated with lower body weight (p = 0.015).
Why this rating
Based on the same high-quality RCT, but the genetic associations are exploratory/subgroup analyses.
Source
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial
Daniel B. Maselli et al. · Obesity · 2022
DOI 10.1002/oby.23481
rct · n=136Cited 116×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →